Navigation Links
EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD

OAK BROOK, Ill., Nov. 5 /PRNewswire/ -- EPI-Q, Inc., a consulting firm providing outcomes research and health economics services to the global biopharmaceutical and healthcare industries, announces the addition of Anthony J. Vita, MD, MPH and Peter Herout, PharmD to their team of clinical professionals. The specialized background of these two practitioners will augment the capabilities EPI-Q is able to offer directly to those clients seeking to enhance the clinical outcomes and cost-effectiveness of patient care.

Both Dr. Herout and Dr. Vita will be responsible for providing clinical support and managing projects within their fields of clinical expertise. "Peter has significant expertise in critical care and cardiology adding to our ability to provide services to hospitals and managed care in both of these important areas. Anthony has clinical skills in mental health, a therapeutic category in which EPI-Q's business is rapidly expanding and his public health training provides additional depth to our methods group," stated EPI-Q President, Mark Jewell.

Dr. Herout has over 8 years experience as a clinical pharmacist. He has spent the majority of his professional career caring for a variety of critically ill patient populations. His most recent practice and research interests have included severe trauma, cardiothoracic surgery, sepsis, glycemic control, infectious diseases, renal replacement therapy, and nutrition support. Before joining EPI-Q, Dr. Herout spent 4 years with Advocate Christ Medical Center in Oak Lawn, Illinois. His contributions to the medical literature have included articles published in Critical Care Medicine and the American Journal of Health-System Pharmacy. He received his PharmD degree from the University of Illinois at Chicago, and completed one-year ASHP-accredited residencies in Pharmacy Practice and Critical Care.

Prior to joining EPI-Q, Dr. Vita worked as a resident physician at the University of Chicago, Department of Psychiatry for 3 years. He has also practiced in a variety of hospital settings including ICU, CCU, general medicine, general pediatrics, pediatric ICU, obstetrics, and neurology. Among the journals publishing Dr. Vita's works are The New England Journal of Medicine, The Journal of Pharmacology and Experimental Therapeutics, and The American Journal of Physiology. Dr. Vita received his Doctor of Medicine degree from Stanford University and Master of Public Health degree from Harvard University.

EPI-Q, Inc. ( provides life sciences companies and healthcare providers and payer organizations with evidence-based solutions that elucidate the value of medical technology and improve health outcomes and cost-effectiveness. EPI-Q's professionals have extensive expertise in medicine, pharmacy, epidemiology, biostatistics, economics, business and healthcare administration. In addition, many of these experts maintain academic affiliations, publish and present frequently on issues pertaining to quality improvement and outcomes management.


Mark Jewell, PhD Andrew M. Baker

President Vice President - Business Development

EPI-Q, Inc. EPI-Q, Inc.

Tel: 630.570.5505 Tel: 914.358.3264

Fax: 630.570.5506 Fax: 914.358.3265

Email: Email:

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):